With recent buoyancy in the cannabis stocks, as reflected in AdvisorShares Pure US Cannabis ETF (NYSE: MSOS), the excitement surrounding future price action has been downright euphoric in recent times. Whether it be calamitous chatter CannTwit on X, or trending Top 5 of the infamous momentum stock forum r/wallstreetbets, undoubtedly, the possibility of two reform initiatives had catalyzed the market. However, yesterday’s double-barrel capital raises has seemingly put a brake on this iteration of the sector rally.
The first capital raise news to grace the market was courtesy of Columbia Care (CSE: CCHW) (OTC:CCHWF), which struck a subscription deal with institutional investors to purchase equity. Under the private placement agreement, the company will sell 22,244,210 units, at a rate of C$1.52 per Unit, with a half-warrant exercisable at a price of C$1.96 per share for a term of three years. Aggregate gross proceeds of the placement is expected to generate approximately US$25 million in the initial tranche, with an investor option to purchase US$25 million in additional Units.
Not to be outdone, Canopy Growth (NASDAQ: CGC) also announced a private placement that hit the wires just thirteen minutes later, when the company finalized subscription agreements with specific institutional investors as part of a private placement offering. The offering involved a total of 22,929,468 units, each priced at US$1.09 per Unit, resulting in a combined gross sum of approximately US$25,000,000. This is excluding an over-allotment option to acquire an addition 22,929,468 Units on similar pricing terms.
The significance of these two raises within the wider context is important. In our estimation, it was a clear indicator that certain cash-challenged operators are taking advantage of the current exuberance to raise additional capital. And with many MSOs currently facing the same low working capital predicament, the raises are making price point sensitive investors wary on where to purchase equity.
Specifically, dilution concerns tend to crop up when companies within an industry opt to raise capital by issuing new shares, whether through secondary offerings or private placements. Such dilution can be of worry for investors, especially when the capital infusion is substantial or is anticipated to be needed multiple times within a relatively short period. As a result, it exerts downward pressure on the stock prices of these companies. This apprehension can then ripple out to affect the wider industry as investors take a step back to reevaluate their positions.
Significantly, both the Columbia Care (now The Cannabist) and Canopy Growth deals were priced well below market, giving fresh investors pause. After all, nobody wants to wake up one day to news that a capital raise has occurred 17% and 23% below the last traded price, as which occurred with the aforementioned.
Capital Raising Expected, However A Signal The Rally Was Mature
It’s crucial to understand that the cannabis equity market is still largely retail and small fund oriented. As such, responses to capital raises can play on market sentiment perhaps more than more liquid and institutional-based sectors. With cannabis stocks entrenched in structural bear market conditions stemming back to Spring 2021—and with reform hopes dashed on several occasions in the past—it doesn’t take much to spook this fickle crowd.
In particular, the dilution is a source of worry for investors, especially when the capital infusion is substantial or expected to widespread with a sector. With several MSO balance sheets borderline on requiring additional working capital, the placements likely prompted new capital to think twice about buying the recent highs.
Put another way: the gung-ho indiscriminate buying phase of the current iteration of the rally is likely over—at least until the news cycle cooperates. But take heart: it can just as easily fire back up upon the right reform catalyst. Once again, the fate of cannabis equities lies upon the whims of politicians and regulators that populate Capitol Hill.
As of publishing time, MSOS ETF was lower by 7.78% to $8.18 per share on the New York Stock Exchange.
The post Canopy Growth & Columbia Care Capital Raises Put The Brakes On MSOs Rally appeared first on The Dales Report.nasdaq equities stocks etf
Everything Now: eating disorder recovery is treated with sensitivity and nuance in Netflix comedy drama
The series should be praised for recognising that it’s not just white, middle-class girls who experience eating disorders.
Netflix couldn’t have chosen a more resonant title than Everything Now for their new comedy drama series. When I came out of a residential clinic in 2009 for treatment of anorexia, I did a parachute jump, started volunteering and decided to have a baby on my own. Some of these were impulsive – yet heartfelt – attempts to “catch up” on a life that had been passing me by.
This sense of things moving on while you have been trapped in the depths of an eating disorder is probably even more potent in the intensified temporal rhythms of teenage years.
As Mia Polanco (Sophie Wilde), the 16-year-old protagonist of Everything Now, asks as the school bus conversation jostles around her: “Fuck. How can I have missed so much in seven months?”
This article is part of Quarter Life, a series about issues affecting those of us in our twenties and thirties. From the challenges of beginning a career and taking care of our mental health, to the excitement of starting a family, adopting a pet or just making friends as an adult. The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.
You may be interested in:
Everything Now is a thoughtful, sensitive and entertaining journey through Mia’s experience of teenage life following her discharge from the eating disorder inpatient unit she has been confined to for seven months.
The image of eating disorders
White, middle-class girls with anorexia have long since dominated the representation in film and TV. But eating disorders cut across ethnic boundaries.
Although there can never be any simple correlation between popular media representations of eating disorders and reality, they play a role in shaping wider understandings of eating problems. This includes who might be affected by them. As a result, this under-representation contributes to a culture in which people from minority ethnic backgrounds are under-diagnosed and less likely to access treatment.
Everything Now should be praised for recognising that it’s not just white, middle-class girls who experience eating disorders.
Also, a significant part of the early plot focuses on Mia’s crush on a female student. Historically, clumsy assumptions have supposed that LGBTQ+ girls and women are somehow more “protected” from eating issues than their heterosexual counterparts. This has long since been challenged. Research has shown that sexual minorities may be more at risk due to the complex relationships between oppression, gender identity and sexuality.
Everything Now is one of the first TV shows about eating disorders that did not make me cringe. It is sensitive, carefully researched and it resonated.
The show does a good job of exploring the complexities of recovery – a long and uncertain process that is rarely depicted, perhaps because it is seen as less arresting than the descent into the illness.
Switching between flashbacks of her time in the clinic and her present life at school and home, Mia’s voiceover communicates her struggles and anxieties. It also shows how difficult it is to navigate other people’s perceptions of recovery. Her grandmother, for example, bakes her a coconut sponge to welcome her home, to which Mia internally exclaims: “You’ve got to be fucking kidding me.”
Her grandma then pinches her cheek and says: “You look so wonderful, so healthy.” The implied link between flesh and healthiness can make such comments a minefield for people in recovery.
Mia aims to throw herself back into adolescence, but the series poignantly explores her new status as an insider and outsider – how she is irrevocably changed by her eating disorder.
As the camera pans over the nibbles and drinks at a party she asks: “How can they just eat and drink? How am I 16 and I can’t just do that?” This captures the way spontaneity with food and drink becomes utterly unimaginable, not only during the throes of an eating disorder but during the pressures, regimens and routines of a recovery meal plan.
The voiceover is particularly good at showcasing the disjuncture between Mia’s eagerness and how her eating disorder pulls the brake: “Shots, OK. At least I can track what’s in that. Maybe I can skip something tomorrow. I need to show them I’m better. That I can be normal.” She is both present and not present – one of her peers yet so separate.
Everything Now depicts positive moments of recovery too, in ways that are touching and insightful. As Mia walks to school for the first time, she reflects on “All the everyday beauty I forgot how to see – and all the things I get to rediscover now.”
While the eating disorder has made the everyday strange (the snacks and drinks at the party seem impossible) it has also made the everyday more beautiful. The scene reminded me of a quote from a student in sociologist Paula Saukko’s 2008 book The Anorexic Self: “I used to be able to see the sky, but now I only think about food.”
Everything Now is an original, heartwarming and insightful story of learning to see the sky again.
Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Su Holmes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.link treatment recovery
Surviving and Thriving in an Ugly Stock Market
Surviving and Thriving in an Ugly Stock Market
After a wonderful 2021 for stock investors, the last two years have been rough, to say the…
After a wonderful 2021 for stock investors, the last two years have been rough, to say the least. The next sustained bull market seems to remain in the unknown future.
So let’s look at a couple of market strategies that have worked and will do so no matter how the stock market goes…
It is extremely difficult (for most investors, I’d say it is impossible) to time the market and generate above-average returns from capital gains. I recommend strategies that provide consistent returns.
My Dividend Hunter service focuses on investing in high-yield securities. It has been my best-performing strategy over the last year. Many investors get high-yield investing wrong and stay too focused on share prices. The focus of high-yield investing should be on the cash income stream. Yield means dividends, which are cash returns that don’t go away when share prices go down.
The goal of high-yield investing is to build a stable and growing income stream. I advise my Dividend Hunter subscribers to track their portfolio income quarter after quarter. As long as the income increases, they are fine, and it doesn’t matter what happens to share prices.
Over the long term, a high-yield strategy naturally leads to buying during market downturns. When share prices drop, yields increase, making shares more attractive for income-focused investors. If you make regular monthly contributions, you will buy more shares when the market is down and fewer at market highs. The result will be a lower average share cost and a higher yield on cost.
Starwood Property Trust (STWD) is a long-term Dividend Hunter recommendation. I started my solo 401k in late 2017 and bought my first shares of STWD in January 2018. The first purchase cost $21.18 per share. Over the last six years, I have added STWD shares at prices ranging from $10.96 (at the bottom of the pandemic-triggered crash) to $24.38. My average cost is $17.45 per share, giving me a yield on cost of 11%.
For my Monthly Dividend Multiplier service, I use a dividend growth strategy. You can build wealth by investing in stocks that grow their dividends. You will likely get frustrated with the process before you reach your wealth target.
History shows that the compound annual total returns from a dividend growth stock will end up very close to the average dividend growth rate plus the average dividend yield. For the famous Dividend Aristocrats, this math puts annual returns in the single digits. The realized returns tend to get lost in the short-term market swings, but the math works as you look at five-year and longer time frames.
For the Monthly Dividend Multiplier portfolio, I search out dividend growth stocks where the yield plus dividend growth math gives numbers in the mid-teens. That level of compounding returns will double your money about every five years.
I’ve ensured that the portfolio is diversified across as many sectors as possible that meet my dividend criteria. I track results quarterly and am always surprised by the short-term gains and losses among individual stocks and market sectors. For example, for the third quarter, the Monthly Dividend Multiplier individual returns ranged from gains of over 30% to a loss of more than 30%.
To take advantage of the intermediate swings, I have set weightings for the portfolio stocks, and we rebalance every quarter.
NextEra Energy Partners (NEP) was the big loser for the third quarter. The company reduced its dividend growth guidance from 12% to 15% per year to 5% to 8% through 2026. The NEP share price dropped by 20% in one day and is down double that year to date. But… after the drop, NEP now yields 9%. Add that to 5% dividend growth, and you have potentially mid-teens total annual returns in the future.
Our end-of-Q3 rebalance allowed my subscribers to average down their cost basis on NEP to benefit from future dividend growth.
For years, I’ve stressed investing in dividend stocks for income. However, I’ve recently stumbled on a strategy that could generate up to triple digit winners from dividend stocks. This is brand new and you can see the strategy here.
Ripple’s XRP price jumps 5% fuelled by Singapore licensing acquisition amidst crypto market downturn
Ripple’s XRP emerged as one of the rare gainers during a subdued 24 hours in the cryptocurrency market that saw Bitcoin (BTC) and other top digital assets…
Data from CryptoSlate reveals that XRP surged by approximately 5%, reaching $0.53018 as of press time. This uptick follows Ripple’s significant victories during the reporting period as it secured licensing in Singapore and Judge Analisa Torres rejected the U.S. Securities and Exchange Commission’s (SEC) plea for an interlocutory appeal.
Ripple’s Singapore licensing
Earlier today, Ripple said its subsidiary, Ripple Markets APAC Pte Ltd, secured a “full” Major Payments Institution (MPI) license from the Monetary Authority of Singapore (MAS) to provide digital payment token services in the country. The crypto payment country received an in-principle approval from the regulator in June.
The MPI license enables businesses to operate free from daily and monthly transaction limits. To qualify, the business must possess a Singaporean-registered company or branch, maintain a permanent business address for record-keeping, have a minimum capital of $250,000, and appoint at least one director with Singaporean citizenship or residency.
Ripple CEO Brad Garlinghouse described Singapore as a “progressive jurisdiction” that has ” developed into one of the leading fintech and digital asset hubs striking a balance between innovation, consumer protection, and responsible growth.”
Besides that, Judge Torres’s decision provides a closing chapter to the legal tussle between the company and the SEC for this year, with both parties scheduled for trial by April 23, 2024.
Selling pressure on the horizon
Despite this recent surge, XRP still confronts substantial selling pressure due to Ripple recently releasing one billion tokens from its escrow system.
While the crypto payment firm immediately relocked 800 million XRP, the company still holds 200 million tokens that could add more than $100 million in selling pressure to the market, potentially altering the current upward momentum of the asset.
The post Ripple’s XRP price jumps 5% fuelled by Singapore licensing acquisition amidst crypto market downturn appeared first on CryptoSlate.cryptocurrency bitcoin crypto btc xrp crypto
Eli Lilly to buy radiopharma company Point Biopharma for $1.4B as PhIII readout looms
Bitcoin, Solana products lead first crypto investment inflow since mid-August
The RBA’s battle with inflation: Examining the latest data points
3 Key Relationships to Help Assess Market Direction
Major Asset Classes | September 2023 | Performance Review
New tool reveals how drugs affect men, women differently — and will make for safer medications
One-third of all CFTC crypto enforcement actions took place this year — Chairman Behnam
ICE (Black Knight) Mortgage Monitor: “Home Prices Set Yet Another Record in August”
Book describes Sam Bankman-Fried with little attention span or respect for appointments
Buy Love, Sell Fear
Uncategorized23 hours ago
Eli Lilly to buy radiopharma company Point Biopharma for $1.4B as PhIII readout looms
International24 hours ago
Swiss franc slips as inflation falls
Uncategorized13 hours ago
Cardano stablecoin project gambled away investors’ money before rug: Report
International16 hours ago
Computer model predicts who needs lung cancer screening
International11 hours ago
New robot could help diagnose breast cancer early
Government21 hours ago
Nationwide test of Wireless Emergency Alert system could test people’s patience – or help rebuild public trust in the system
Uncategorized8 hours ago
SEC asks judge to reject Coinbase’s motion to dismiss lawsuit
International18 hours ago
Airlines are being hit by anti-greenwashing litigation – here’s what makes them perfect targets